Search

Displaying results 5601 - 5610 of 10000 in total
  1. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  2. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  3. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    [T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]

  4. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  5. Drug

    Benorilate

    go.drugbank.com/drugs/DB13657
    Approved

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  6. Indication

    Senile chorea

    go.drugbank.com/conditions/DBCOND0025571
    Drugs: Deutetrabenazine · Fluphenazine · Tetrabenazine · Tiapride · Valbenazine
    Synonyms: Chorea NOS, Chronic progressive non-hereditary chorea (disorder)
  7. Drug

    Implitapide

    go.drugbank.com/drugs/DB04852
    Investigational

    Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

  8. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.

  9. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    It is a new type of antidepressant drug with anxiolytic activity. … It is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments.

  10. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]